West Announces Third-Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
West Pharma (WST) Tops Q3 EPS by 16c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus
October 22, 2020 6:11 AM EDTWest Pharma (NYSE: WST) reported Q3 EPS of $1.15, $0.16 better than the analyst estimate of $0.99. Revenue for the quarter came in at $548 million versus the consensus estimate of $510.14 million.
Third-Quarter 2020 Summary (comparisons to prior-year period)
Net sales of $548.0 million grew 20.1%; organic sales growth was 18.2%.Reported-diluted EPS of $1.09 increased 45%.Adjusted-diluted EPS of $1.15 increased 46%.Company is raising full-year 2020 net sales guidance to a new range of $2.10 billion and $2.11 billion.Company is raising full-year 2020 adjusted-diluted EPS guidance to a new range of $4.50 and $4.55."Adjusted-diluted EPS" and "organic sales... More
